NasdaqGS - Nasdaq Real Time Price USD
Tourmaline Bio, Inc. (TRML)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 7:39 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
Operating Expense
61,021.00
45,409.00
19,701.00
Operating Income
-61,021.00
-45,409.00
-19,701.00
Other Income Expense
11,730.00
3,285.00
--
Pretax Income
-49,291.00
-42,124.00
-19,701.00
Net Income Common Stockholders
-49,291.00
-42,124.00
-19,701.00
Diluted NI Available to Com Stockholders
-49,291.00
-42,124.00
-19,701.00
Basic EPS
-1.92
-8.87
-0.97
Diluted EPS
-1.92
-8.87
-0.97
Basic Average Shares
25,647.76
4,747.00
20,336.77
Diluted Average Shares
25,647.76
4,747.00
20,336.77
Total Operating Income as Reported
-61,021.00
-45,409.00
-19,701.00
Total Expenses
61,021.00
45,409.00
19,701.00
Net Income from Continuing & Discontinued Operation
-49,291.00
-42,124.00
-19,701.00
Normalized Income
-49,291.00
-42,124.00
-19,701.00
EBIT
-61,021.00
-45,409.00
-19,701.00
EBITDA
-60,981.00
-45,376.00
-19,695.00
Reconciled Depreciation
40.00
33.00
6.00
Net Income from Continuing Operation Net Minority Interest
-49,291.00
-42,124.00
-19,701.00
Normalized EBITDA
-60,981.00
-45,376.00
-19,695.00
12/31/2022 - 5/7/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SYRE Spyre Therapeutics, Inc.
32.76
0.00%
DNTH Dianthus Therapeutics, Inc.
29.05
+3.64%
LXEO Lexeo Therapeutics, Inc.
11.12
+22.20%
ACLX Arcellx, Inc.
96.86
+1.67%
VRDN Viridian Therapeutics, Inc.
24.98
+2.97%
NMRA Neumora Therapeutics, Inc.
16.49
-2.77%
MLYS Mineralys Therapeutics, Inc.
14.40
+3.75%
ASND Ascendis Pharma A/S
129.90
+2.56%
KROS Keros Therapeutics, Inc.
61.25
+0.26%
NGNE Neurogene Inc.
54.40
+2.80%